6-Hydroxydopamine therapy in glaucoma.
At the inception of this study, 6-hydroxydopamine (6-HD) was administered to 137 eyes of 100 glaucoma patients by subconjunctival injection (27 applications) and later by iontophoresis (202 applications). Eighty-four patients were receiving maximum medical therapy, and 24 had had previous glaucoma surgery. Seventy-seven had primary open-angle glaucoma. In 49 patients with data adequate for analysis, 6-HD therapy was effective in 41%, questionable in 31%, and not effective in 28%. The median peak-pressure drop was 13 mm Hg from a baseline of 26 by subconjunctival injection and 6 mm Hg from a baseline of 24 by iontophoresis. The median effective period before return to baseline pressure was 2.5 months. There was a direct correlation between the effectiveness of epinephrine therapy with and without 6-HD. Iontophoresis is a much more practical method for the administration of 6-HD.
D003228:Conjunctiva; D004837:Epinephrine / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D006892:Hydroxydopamines / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D007478:Iontophoresis
D006892:Hydroxydopamines; D004837:Epinephrine